FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma-Reference-Cited by-同舟云学术

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

Published:2013-02-11 Issue:4 Volume:57 Page:1407-1415
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Arao Tokuzo,Ueshima Kazuomi,Matsumoto Kazuko,Nagai Tomoyuki,Kimura Hideharu,Hagiwara Satoru,Sakurai Toshiharu,Haji Seiji,Kanazawa Akishige,Hidaka Hisashi,Iso Yukihiro,Kubota Keiichi,Shimada Mitsuo,Utsunomiya Tohru,Hirooka Masashi,Hiasa Yoichi,Toyoki Yoshikazu,Hakamada Kenichi,Yasui Kohichiroh,Kumada Takashi,Toyoda Hidenori,Sato Shuichi,Hisai Hiroyuki,Kuzuya Teiji,Tsuchiya Kaoru,Izumi Namiki,Arii Shigeki,Nishio Kazuto,Kudo Masatoshi

Funder

Third-Term Comprehensive 10-Year Strategy for Cancer Control

National Cancer Center Research and Development Fund

Grant-in-Aid for Scientific Research

Publisher

Wiley

Subject

Hepatology

Reference21 articles.

1. Cancer statistics, 2005;Jemal;Ca Cancer J Clin,2005

2. Recurrence of hepatocellular carcinoma after surgery;Yamamoto;Br J Surg,1996

3. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res,2004